Oluyemi Okupe Sells 23,090 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 23,090 shares of Hims & Hers Health stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $35.72, for a total transaction of $824,774.80. Following the completion of the transaction, the chief financial officer owned 94,333 shares in the company, valued at approximately $3,369,574.76. This represents a 19.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.81, for a total value of $853,513.47.
• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total value of $853,513.47.
• On Friday, October 17th, Oluyemi Okupe sold 11,592 shares of Hims & Hers Health stock. The stock was sold at an average price of $57.13, for a total value of $662,250.96.
• On Friday, October 3rd, Oluyemi Okupe sold 11,595 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.72, for a total value of $669,263.40.
• On Monday, September 29th, Oluyemi Okupe sold 85,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $60.20, for a total value of $5,117,000.00.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $34.54 on Thursday. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The business has a 50 day simple moving average of $40.50 and a 200-day simple moving average of $48.08. Hims & Hers Health, Inc. has a 12 month low of $23.97 and a 12 month high of $72.98. The stock has a market capitalization of $7.86 billion, a PE ratio of 63.95, a price-to-earnings-growth ratio of 6.88 and a beta of 2.41.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The firm had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business’s quarterly revenue was up 49.2% on a year-over-year basis. During the same quarter last year, the business earned $0.32 earnings per share. Equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its board has initiated a stock repurchase program on Monday, November 17th that permits the company to buyback $250.00 million in shares. This buyback authorization permits the company to purchase up to 3% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on HIMS shares. Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. BTIG Research reiterated a “buy” rating and issued a $85.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Bank of America boosted their target price on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a research report on Tuesday, November 4th. Finally, UBS Group set a $32.00 price target on shares of Hims & Hers Health in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and an average target price of $45.50.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Ethic Inc. purchased a new position in shares of Hims & Hers Health in the 2nd quarter worth $348,000. Lake Hills Wealth Management LLC purchased a new position in shares of Hims & Hers Health in the 2nd quarter worth about $277,000. Intellectus Partners LLC purchased a new position in shares of Hims & Hers Health in the 2nd quarter worth about $3,043,000. Occidental Asset Management LLC acquired a new position in shares of Hims & Hers Health in the 2nd quarter valued at about $305,000. Finally, Dakota Wealth Management purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth about $354,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.